Cardiovascular HealthApr 3, 2026
Only about 16% of cardiologists correctly identify where the V1 electrode should go on your chest. Among paramedics, just 5 to 6% place all six chest leads in the right spots. That is not a typo. The people reading your heart tracings are frequently working with tracings recorded from the wrong locations on your body.
This matters because even a two-centimeter shift in electrode position can alter the squiggly lines on an ECG enough to mimic a heart attack, hide one, or trigger a cascade of unnecessary tests and treatments. Research consistently finds that roughly half or more of ECG recordings in clinical settings have at least one significant lead out of place.
Cardiovascular HealthApr 3, 2026
Mobitz type 2 second-degree AV block is one of those diagnoses that sounds technical but carries a very direct, practical message: your heart's electrical wiring has a problem that tends to get worse, and it usually means you need a pacemaker. Even if you feel fine. What makes it especially tricky is that it is often misidentified on ECG, confused with more benign rhythm patterns that don't require the same level of intervention.
The distinction matters because true Mobitz type 2 is strongly associated with progression to complete heart block, fainting episodes known as Stokes-Adams syncope, and death. Getting the diagnosis right is the difference between watchful waiting and permanent pacemaker implantation.
Cardiovascular HealthApr 3, 2026
Grade 1 diastolic dysfunction shows up on echocardiograms all the time, and it's routinely brushed off. Your heart's relaxation phase is slightly stiff, but your filling pressures look fine, and you probably feel nothing. The problem: community data link this silent finding to higher all-cause and cardiovascular mortality over 15 to 20 years, even when it appears completely isolated with no other echo abnormalities. It also predicts future heart failure, stroke, and end-stage renal disease, particularly when it shows up between ages 40 and 55.
So if someone tells you this is just what happens with aging and not worth worrying about, that's incomplete at best. Grade 1 diastolic dysfunction is the earliest detectable stage of abnormal left-ventricular filling, a point where the trajectory can still be changed.
Heart HealthApr 3, 2026
Standard cholesterol panels measure how much cholesterol sits inside your LDL particles. But cardiovascular risk depends on the number of atherogenic particles circulating in your blood, not the cholesterol mass they carry. The ApoB test measures that particle count directly. Over the past decade, evidence from genetic studies, prospective cohorts, and clinical trials has shown that ApoB predicts cardiovascular events more accurately than LDL cholesterol (LDL-C) alone, particularly in people with metabolic syndrome, insulin resistance, or elevated triglycerides.
MedicationsApr 3, 2026
Repatha (evolocumab) is a PCSK9 inhibitor given as a subcutaneous injection to lower LDL cholesterol. It is prescribed for adults whose cholesterol remains above goal despite statin therapy, including those with established cardiovascular disease or familial hypercholesterolemia. The injection can be self-administered at home using a prefilled autoinjector or syringe, with clinical studies showing approximately 95 percent of at-home doses completed successfully.
MedicationsApr 3, 2026
Rosuvastatin is the most potent statin per milligram, lowering LDL cholesterol by 43% to 55% across its dose range. Your starting dose depends on cardiovascular risk, how far LDL needs to drop, and whether you have existing heart disease.
MedicationsApr 3, 2026
Leqvio (inclisiran) is a twice-yearly injection that lowers LDL cholesterol by silencing PCSK9 production in the liver. Across multiple phase 3 trials enrolling over 3,600 patients, its overall safety profile was comparable to placebo, with injection-site reactions as the main differentiator. Here is what the clinical trial data actually shows about side effects, long-term tolerability, and safety in specific patient groups.
MedicationsApr 3, 2026
Repatha (evolocumab) is a PCSK9 inhibitor that lowers LDL cholesterol by about 55-60% on top of statins. It is prescribed when statins alone are not enough or when patients cannot tolerate them. Repatha works differently from statins, targeting a specific protein in the liver rather than blocking cholesterol production. Its side effect profile reflects that difference. Here is what clinical trial data and post-marketing surveillance actually show.
MedicationsApr 3, 2026
Rosuvastatin and atorvastatin are the two most prescribed high-intensity statins. Both lower LDL cholesterol and reduce cardiovascular risk, but they differ in potency, side effect profiles, and how individual patients respond. Here is what the research shows.
MedicationsApr 3, 2026
Praluent (alirocumab) and Repatha (evolocumab) are injectable PCSK9 inhibitors prescribed when statins alone can't bring LDL cholesterol low enough. Both cut LDL by 50-65% and reduce heart attacks and strokes. The real differences are subtle but worth understanding.
MedicationsApr 3, 2026
Rosuvastatin 5 mg is one of the most studied low-dose statins available. Clinical trial data from over 16,000 patients shows it is well tolerated, with serious side effects occurring at rates similar to placebo.
MedicationsApr 3, 2026
Ezetimibe is an FDA-approved cholesterol absorption inhibitor that lowers LDL-C by 15-20% when used alone and by an additional 25% when added to a statin. It works differently from statins, blocking cholesterol uptake in the small intestine rather than suppressing production in the liver. If you are considering Ezetimibe as part of your cholesterol management, this article covers what the published research says about its side effects, with specific numbers from large trials.
